Julie Rathbun
Investor Relations Contact at ATHIRA PHARMA, INC.
Julie Rathbun active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ATHIRA PHARMA, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - | |
| Rathbun Communications, Inc. | Founder | 31/12/2003 | - |
| President | 31/12/2003 | - |
Career history of Julie Rathbun
Former positions of Julie Rathbun
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNE DESIGN CORP | Public Communications Contact | - | 01/04/2019 |
| NEUROGENE INC. | Public Communications Contact | - | - |
| SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - | - |
Training of Julie Rathbun
| Western Washington University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Public Communications Contact | 4 |
| Founder | 1 |
| President | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
| Rathbun Communications, Inc. |
- Stock Market
- Insiders
- Julie Rathbun
- Experience
